Helen Tayton-Martin, Adaptimmune co-founder, named CEO of Evaxion

Evaxion Biotech A/S (NASDAQ:EVAX) hired Helen Tayton-Martin as CEO, effective Nov. 24. She is a co-founder of Adaptimmune Therapeutics plc (NASDAQ:ADAP), where she was COO and later chief business and strategy officer during her 17 years with the company. Tayton-Martin will step down from her seat on the board, and Jens Bitsch-Norhave will join the Copenhagen based company as observer and adviser to the board, with plans to seek election at the next AGM. Birgitte Rønø, who served as interim CEO, will continue in her role as CSO. 

Kevin Ali resigned as CEO and a director of Organon & Co. (NYSE:OGN) and the company terminated its head of U.S. commercial & government affairs after an independent, internal investigation found improper wholesaler sales practices for its Nexplanon birth control implant in the U.S. The specialty pharma company named Joseph Morrissey, EVP and head of manufacturing & supply, interim CEO. Board Chair Carrie Cox will serve as executive chair on an interim basis to support Morrissey. Robert Essner, a director, will become lead independent director. Ali will not be entitled to severance or equity-related retirement benefits in connection with his resignation...